Castration-resistant prostate cancer: [177Lu]Lu-PSMA-617 versus cabazitaxel Comment

被引：0
|
作者：
Todenhoefer, Tilman [1 ]
机构：
[1] Studienpraxis Urol, Steinengrabenstr 17, D-72622 Nurtingen, Germany
来源：
AKTUELLE UROLOGIE | 2023年 / 54卷 / 04期
关键词：
D O I：
10.1055/a-2084-8214
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [2] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-61 7 versus cabazitaxel
    Lorenz, Kunzell Judith
    AKTUELLE UROLOGIE, 2023, 54 (04) : 269 - 269
  • [3] LuCAB: A PHASE I/II TRIAL EVALUATING CABAZITAXEL IN COMBINATION WITH (177Lu)Lu-PSMA-617 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Buteau, James
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 71 - 71
  • [4] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Philipp E. Hartrampf
    Franz-Xaver Weinzierl
    Andreas K. Buck
    Steven P. Rowe
    Takahiro Higuchi
    Anna Katharina Seitz
    Hubert Kübler
    Andreas Schirbel
    Markus Essler
    Ralph A. Bundschuh
    Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276
  • [5] LuCAB: A Phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Kostos, Louise
    Buteau, James P.
    Kong, Grace
    Opar, Petra
    Di Lulio, Juliana
    Fahey, Michael
    Fettke, Heidi
    Furic, Luc
    Hofman, Michael S.
    Azad, Arun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 77 - 77
  • [6] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Hartrampf, Philipp E.
    Weinzierl, Franz-Xaver
    Buck, Andreas K.
    Rowe, Steven P.
    Higuchi, Takahiro
    Seitz, Anna Katharina
    Kuebler, Hubert
    Schirbel, Andreas
    Essler, Markus
    Bundschuh, Ralph A.
    Werner, Rudolf A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (09) : 3269 - 3276
  • [7] [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
    Hofman, Michael S.
    Emmett, Louise
    Sandhu, Shahneen
    Iravani, Amir
    Joshua, Anthony M.
    Goh, Jeffrey C.
    Pattison, David A.
    Tan, Thean Hsiang
    Kirkwood, Ian D.
    Ng, Siobhan
    Francis, Roslyn J.
    Gedye, Craig
    Rutherford, Natalie K.
    Weickhardt, Andrew
    Scott, Andrew M.
    Lee, Sze-Ting
    Kwan, Edmond M.
    Azad, Arun A.
    Ramdave, Shakher
    Redfern, Andrew D.
    Macdonald, William
    Guminski, Alex
    Hsiao, Edward
    Chua, Wei
    Lin, Peter
    Zhang, Alison Y.
    McJannett, Margaret M.
    Stockler, Martin R.
    Violet, John A.
    Williams, Scott G.
    Martin, Andrew J.
    Davis, Ian D.
    LANCET, 2021, 397 (10276): : 797 - 804
  • [8] COST-EFFECTIVENESS OF [177LU]LU-PSMA-617 IN PROGRESSIVE PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Brockbank, J.
    Hancock, H.
    Khare, A.
    Joshi, P.
    Risson, V
    VALUE IN HEALTH, 2024, 27 (12) : S121 - S121
  • [9] Lu-PSMA-617 for metastatic castration-resistant Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2022, 53 (02) : 106 - 106
  • [10] Personalized dosimetry assessment of [177Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer
    Kazemi-Jahromi, Mahmood
    Yazdani, Elmira
    Karamzade-Ziarati, Najme
    Asadi, Mahboobeh
    Sadeghi, Mahdi
    Geramifar, Parham
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2024, 100 (11) : 1551 - 1559
12345